Author

A. H. Sims

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Assay:bulk RNA-seq· 5 Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 4 Research Focus:differential expression· 4 Research Focus:cell type annotation· 3 Assay:proteomics· 2 Approach:statistical model· 2

Frequent Co-Authors

R. B. Clarke· 3 shared A. K. Turnbull· 2 shared A. Santiago-Gomez· 2 shared B. M. Simoes· 2 shared J. M. Dixon· 2 shared S. J. Howell· 2 shared A. Fernando· 1 shared A. Li· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. B. Clarke

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Toll-like receptor 2 orchestrates a potent anti-tumor response in non-small cell lung cancer

F. R. Millar, A. Pennycuick, M. Muir, A. Quintanilla, P. Hari, E. Freyer, P. Gautier, A. Meynert, V. H. Teixeira, J. Connelly, W. A. Wallace, A. H. Sims, M. C. Frame, L. Boulter, S. M. Janes, , J. C. Acosta

This study identifies TLR2 as a tumor suppressor in early-stage lung cancer, showing its role in immune surveillance and tumor growth reduction through synthetic agonist administration.

bioRxiv · Jun 4, 2021 · PreprintCancer Biology

LBH is a cancer stem cell- and metastasis-driving oncogene essential for WNT stem cell function in breast cancer

K. Garikapati, K. Ashad-Bishop, S. Hong, R. Qureshi, M. E. Rieger, L. E. Lindley, B. Wang, D. J. Azzam, M. Khanlari, M. Nadji, C. Jain, D. Kwon, Y. Ban, Z. Gao, S. X. Chen, , K. J. Briegel

This study identifies LBH as a key oncogene driving cancer stem cell function and metastasis in breast cancer through WNT pathway activation.

bioRxiv · Jan 29, 2021 · PreprintCancer Biology

Identification of stromal genes differentially expressed in lobular breast cancer highlights role for pregnancy-associated-plasma protein-A

L. Gomez-Cuadrado, H. Zhao, M. Souleimanova, P. R. Noer, A. K. Turnbull, C. Oxvig, N. Bertos, J. M. Dixon, M. Park, A. H. Sims, V. G. Brunton

The paper identifies stromal genes differentially expressed in lobular breast cancer, highlighting pregnancy-associated-plasma protein-A (PAPPA) as a potential prognostic marker.

bioRxiv · Apr 24, 2020 · PreprintCancer Biology

Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

B. M. Simoes, A. Santiago-Gomez, C. Chiodo, T. Moreira, D. Conole, S. Lovell, D. Alferez, R. Eyre, K. Spence, A. Sarmiento-Castro, B. Kohler, M. Lanzino, S. Ando, E. Marangoni, A. H. Sims, , R. B. Clarke

This study shows that SFX-01 reduces CSC activity in ER+ breast cancer by inhibiting STAT3 signaling, improving outcomes in endocrine-resistant models.

bioRxiv · Feb 3, 2020Cancer Biology

PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer

A. Santiago-Gomez, I. Dragoni, R. NicAmhlaoibh, E. Trivier, V. Sabin, B. M. Simoes, J. M. Gee, A. H. Sims, S. J. Howell, R. B. Clarke

This study shows PAK4 promotes stemness and progression in ER+ metastatic breast cancer and that targeting PAK4 reverses endocrine resistance.

bioRxiv · Feb 26, 2019Cancer Biology

The milk protein alpha-casein suppresses triple negative breast cancer stem cell activity via STAT and HIF-1alpha signalling pathways in breast cancer cells and fibroblasts

K. E. Garner, R. Lamb, A. H. Sims, R. B. Clarke

This study shows alpha-casein suppresses triple negative breast cancer stem cell activity through STAT and HIF-1alpha pathways, with clinical data linking high alpha-casein expression to better patient outcomes.

bioRxiv · Feb 21, 2019Cancer Biology

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours

C. Selli, A. K. Turnbull, D. A. Pearce, A. Li, A. Fernando, J. Wills, L. Renshaw, J. S. Thomas, J. M. Dixon, A. H. Sims

This study compares molecular changes in dormant and acquired resistant breast cancer tumors during extended letrozole treatment, finding distinct epigenetic alterations in resistant tumors.

bioRxiv · Sep 25, 2018Cancer Biology